FY2025 Earnings Forecast for IKT Issued By Lifesci Capital

Inhibikase Therapeutics, Inc. (NYSE:IKT) – Stock analysts at Lifesci Capital issued their FY2025 earnings per share estimates for Inhibikase Therapeutics in a report issued on Monday, February 23rd. Lifesci Capital analyst G. Maini expects that the company will earn ($0.57) per share for the year. The consensus estimate for Inhibikase Therapeutics’ current full-year earnings is ($0.97) per share. Lifesci Capital also issued estimates for Inhibikase Therapeutics’ Q4 2025 earnings at ($0.12) EPS.

A number of other brokerages have also weighed in on IKT. HC Wainwright reiterated a “buy” rating and set a $8.00 target price on shares of Inhibikase Therapeutics in a research report on Friday, December 26th. Jefferies Financial Group restated a “buy” rating on shares of Inhibikase Therapeutics in a research note on Monday, December 29th. Cantor Fitzgerald started coverage on shares of Inhibikase Therapeutics in a report on Thursday, December 11th. They issued an “overweight” rating and a $4.00 price objective for the company. Finally, Bank of America started coverage on shares of Inhibikase Therapeutics in a report on Wednesday, January 21st. They set a “buy” rating and a $6.00 target price on the stock. Four research analysts have rated the stock with a Buy rating, According to data from MarketBeat, Inhibikase Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $6.00.

Inhibikase Therapeutics Price Performance

Shares of IKT opened at $2.14 on Thursday. Inhibikase Therapeutics has a 1 year low of $1.33 and a 1 year high of $2.58. The stock’s fifty day moving average price is $1.75 and its two-hundred day moving average price is $1.65. The firm has a market cap of $160.87 million, a PE ratio of -0.80 and a beta of 0.84.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. BNP Paribas Financial Markets grew its position in shares of Inhibikase Therapeutics by 70.3% during the 3rd quarter. BNP Paribas Financial Markets now owns 15,640 shares of the company’s stock valued at $25,000 after purchasing an additional 6,458 shares in the last quarter. Barclays PLC boosted its stake in Inhibikase Therapeutics by 10.8% during the fourth quarter. Barclays PLC now owns 94,795 shares of the company’s stock valued at $194,000 after buying an additional 9,217 shares during the period. Virtu Financial LLC grew its position in Inhibikase Therapeutics by 70.1% during the fourth quarter. Virtu Financial LLC now owns 22,869 shares of the company’s stock worth $47,000 after buying an additional 9,423 shares in the last quarter. Sanctuary Advisors LLC purchased a new position in Inhibikase Therapeutics during the fourth quarter worth about $26,000. Finally, Geode Capital Management LLC raised its holdings in shares of Inhibikase Therapeutics by 1.4% in the 4th quarter. Geode Capital Management LLC now owns 1,128,239 shares of the company’s stock valued at $2,313,000 after acquiring an additional 15,665 shares in the last quarter. 3.81% of the stock is owned by institutional investors.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule kinase inhibitors for rare neurodegenerative diseases. Headquartered in New Haven, Connecticut, the company focuses on advancing therapies for central nervous system disorders with high unmet medical need. Its research platform targets key signaling pathways implicated in neuronal survival and degeneration.

The company’s lead investigational candidate, IKT-148009, is a brain-penetrant inhibitor of PDK1 and ABL kinases.